Meeting
2022 ASCO Annual Meeting
A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naïve myelofibrosis.
Authors
Haris Ali
City of Hope, Duarte, CA
Haris Ali , Ashwin Kishtagari , Keri Renee Maher , Sanjay Mohan , Amitabha Mazumder , Kamal Chamoun , Igor Karasik , Eric Sbar , Laura Dugon , Sharon Tamir , Xulong Wang , Josef T. Prchal , Srinivas Kiran Tantravahi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders
Clinical Trial Registration Number
NCT04562389
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7060)
DOI
10.1200/JCO.2022.40.16_suppl.7060
Abstract #
7060
Poster Bd #
291
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naïve myelofibrosis.
First Author: John Mascarenhas
Poster
2024 ASCO Annual Meeting
A phase Ib, open-label study of add-on therapy with CK0804 in participants with myelofibrosis and suboptimal response to ruxolitinib.
First Author: Lucia Masarova
Poster
2023 ASCO Annual Meeting
Selinexor (SEL) plus ruxolitinib (RUX) in JAK inhibitor (JAKi) treatment-naïve patients with myelofibrosis: Updated results from XPORT-MF-034.
First Author: Haris Ali
Poster
2023 ASCO Annual Meeting
EXCEED-ET: A single-arm multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft (P1101) in North American adults with essential thrombocythemia.
First Author: Lucia Masarova